| 1.51 -0.03 (-1.95%) | 06-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.96 | 1-year : | 2.29 |
| Resists | First : | 1.68 | Second : | 1.96 |
| Pivot price | 1.47  |
|||
| Supports | First : | 1.26 | Second : | 1 |
| MAs | MA(5) : | 1.57 |
MA(20) : | 1.42 |
| MA(100) : | 1.38  |
MA(250) : | 3.13 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 72.4 |
D(3) : | 81.3 |
| RSI | RSI(14): 56.4 |
|||
| 52-week | High : | 6.78 | Low : | 0.87 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ALEC ] has closed below upper band by 40.6%. Bollinger Bands are 4.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.54 - 1.55 | 1.55 - 1.56 |
| Low: | 1.35 - 1.36 | 1.36 - 1.37 |
| Close: | 1.49 - 1.51 | 1.51 - 1.53 |
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
Sat, 14 Jun 2025
Alector (ALEC) Appoints Interim CFO as Current CFO Departs | ALE - GuruFocus
Sat, 14 Jun 2025
Alector Provides Executive Leadership Update | ALEC Stock News - GuruFocus
Fri, 13 Jun 2025
Alector Names Neil Berkley as Interim CFO - marketscreener.com
Fri, 13 Jun 2025
Alector Provides Executive Leadership Update - GlobeNewswire
Wed, 11 Jun 2025
Alector shares surge 73% following InvestingPro’s April fair value signal By Investing.com - Investing.com
Tue, 03 Jun 2025
Goldman Sachs Conference: Alector Reveals Next Steps in Fighting Neurodegeneration - Key Updates Coming - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 100 (M) |
| Held by Insiders | 7.411e+007 (%) |
| Held by Institutions | 9.7 (%) |
| Shares Short | 5,580 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.3883e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -139.8 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 216.5 % |
| Return on Equity (ttm) | -17.3 % |
| Qtrly Rev. Growth | 8.834e+007 % |
| Gross Profit (p.s.) | -106.81 |
| Sales Per Share | -125.37 |
| EBITDA (p.s.) | -1.19556e+008 |
| Qtrly Earnings Growth | -1.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -229 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.02 |
| Price to Cash Flow | 1.14 |
| Dividend | 0 |
| Forward Dividend | 5.37e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|